Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139411 | 0.83 | MAOB (0.45) | MAOBPSMB5KMT2APSMB8HSD17B2 | |
| SCHEMBL23627355 | 0.73 | MAOB (0.43) | MAOBPSMB5PSMB8CA2HSD17B2 | |
| SCHEMBL4146586 | 0.73 | MAOB (0.44) | MAOBPSMB5PSMB8CA2HSD17B2 | |
| SCHEMBL5240004 | 0.73 | LMNA (0.44) | MAOBPSMB5PSMB8CMA1CA2 | |
| SCHEMBL24723275 | 0.72 | GPR84 (0.56) | KMT2A | |
| SCHEMBL3244642 | 0.71 | MAOB (0.53) | MAOBPSMB5KMT2AMAOA | |
| SCHEMBL2416801 | 0.71 | LMNA (0.53) | KMT2A | |
| SCHEMBL14270019 | 0.71 | TSHR (0.47) | MAOBPSMB5PSMB8CA2HSD17B2 | |
| SCHEMBL12911153 | 0.71 | PSMB5 (0.46) | MAOBPSMB5PSMB8CMA1CA2 | |
| SCHEMBL669128 | 0.70 | NQO1 (0.43) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELI LILLY AND COMPANY (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2019-06-27 | — | — | US | disclosed |
| US-20180265511-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELI LILLY AND COMPANY | 2018-09-20 | — | — | US | disclosed |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | HYDRA BIOSCIENCES, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | ELI LILLY AND COMPANY | 2012-02-23 | — | — | US | disclosed |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10703754-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | ELANE, CASP3, MMP8 | MAOB 1595/4885PSMB5 2395/4885KMT2A 2953/4885 |
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | MAOB 669/4885PSMB5 2723/4885KMT2A 4200/4885 |
| US-20180265511-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | MAOB 1595/4885PSMB5 2395/4885KMT2A 2953/4885 |
| US-20090143377-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | MAOB 669/4885PSMB5 2723/4885KMT2A 4200/4885 |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | TRPA1, TRPV1, TRPV3 | MAOB 1341/4885PSMB5 3398/4885KMT2A 3764/4885 |
| US-20190194202-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | MAOB 1595/4885PSMB5 2395/4885KMT2A 2953/4885 |
| US-20130059869-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | MAOB 669/4885PSMB5 2723/4885KMT2A 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.